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The carotid atherosclerosis was previously determined by measurement of intima-media thickness (IMT). However, carotid plaque volume and 
composition is more strongly predictive of coronary events than IMT. High-resolution magnetic resonance imaging (MRI) is a noninvasive and 
epochal technique that enables the quantitative, morphological and compositional assessment of the carotid artery. Thus, the CHALLENGER trial 
assessed the effects of rosuvastatin on carotid plaque volume and composition.
Methods:  Prospective, open-label blinded end-points trial was performed using 1.5-T MRI to image carotid atherosclerotic plaques. Patients with 
maximum carotid intima-media thickness (IMT) >= 1.8 mm as measured by ultrasound and a plasma LDL-C of more than 120 mg/dl without statin 
treatment were enrolled from 2007 to 2010. 52 patients were administrated by rosvastatin 5mg/day after baseline MRA. MRI was performed at 
baseline and after 12 months and 24 months of treatment. MRI can measure the fibrous tissue, lipid-rich necrotic core, and calcification as well as 
plaque volume. The primary endpoint was the change in plaque volume and composition as measured by high-resolution MRI after 24 months of 
rosuvastatin therapy.
results:  After 24 months, 38 patients had taken MRI scans to compare by reviewers blinded to clinical data, and temporal sequence of scans. 
LDL-C was significantly reduced from baseline by 46.6%. At 12 and 24 months, there were no significant changes in carotid plaque volume. In all 
patients with a lipid-rich necrotic core (LRNC) without intraplaque hemorrhage (IPH) at baseline, the mean proportion of the vessel wall composed 
of LRNC (%LRNC) decreased by 2.0% at 1-year (P = .0022) and -1.3% at 2-year(P=.0015). Furthermore, reduced volume of LR-NC was significantly 
correlated with decreased level of LDL-C.
conclusions:  Rosuvastatin treatment resulted in significant regression of lipid rich plaque, not plaque volume by MRI. Furthermore, % reduction of 
LRNC volume was positive linear to LDL-C reduction. These findings provide evidence that LDL-C reduction with statin therapy has a beneficial effect 
on plaque composition, as assessed by MRI.
